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S U M M A R Y
Objective: Drug users, particularly drug injectors, are at elevated risk of blood-borne diseases. This study
systematically reviewed the prevalence of hepatitis C virus (HCV) mono-infection and its co-infections
with human immunodeﬁciency virus (HIV) and hepatitis B virus (HBV) in drug users in Iran.
Methods: Searches were conducted in international, regional, and Iranian databases. Documents were
screened, data extracted, and pooled point prevalence and 95% conﬁdence intervals (CI) were calculated.
Results: Overall, 13 821 subjects (87.4% male) with an average age of 32.4 years (95% CI 31–33 years)
from 24 original studies were included in the analysis. The pooled HCV prevalence (95% CI) among drug
users with and without an injection history was 45% (37–54%) and 8% (4–13%), respectively. The pooled
HCV prevalences (95% CI) among individuals with vs. without a history of imprisonment and needle
sharing were 58% (39–77%) vs. 44% (20–68%) and 56% (41–71%) vs. 49% (26–71%), respectively. The
prevalence of HCV/HIV co-infection among injectors was 11% (95% CI 5–16%).
Conclusions: HCV prevalence is high in drug users in Iran, especially among those with a history of
injection drug use, needle sharing, and imprisonment. Drug user-focused HCV prevention and treatment
programs are urgently needed.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
There are currently more than 150 million persons worldwide
who are infected with the hepatitis C virus (HCV),1,2 a blood-borne
virus causing several difﬁcult-to-treat diseases, such as cirrhosis
(5–20% risk in 20–30 years) and liver cancer (1–5% annual risk
depending on the staging of liver ﬁbrosis and cirrhosis).3,4 No
effective HCV vaccine is yet available. As a result, public health and
behavioral interventions are the only means of preventing HCV
infection, particularly among high-risk populations. People who
inject drugs (PWID) are at an especially high risk of contracting
HCV and other fatal blood-borne diseases, including those caused* Corresponding author. Tel.: +1 (510) 8168555; fax: +1 (415) 4760705.
E-mail address: MMalekinejad@ucsf.edu (M. Malekinejad).
http://dx.doi.org/10.1016/j.ijid.2015.09.022
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).by the human immunodeﬁciency virus (HIV) and hepatitis B virus
(HBV).5–7
In 2012, it was estimated that there were nearly 12.7 million
(95% conﬁdence interval (CI) 8.9–22.4 million) PWID worldwide.8
Access to HCV treatment for PWID has been limited due to a
multitude of factors, including low HCV testing coverage and
guidelines that recommend treatment only to drug-abstinent
patients.9 Thus, HCV prevention and treatment among PWID
remains a major public health challenge globally, especially in
countries with high rates of injection drug use such as Iran.10–13
The recreational use of opium smoking in Iran has been
widespread for centuries. Over the past three decades, opium
consumption in the country has been greatly inﬂuenced by its
geographic proximity to neighboring Afghanistan, the world’s
largest opium producer.8,14 In recent decades, there has been a
shift in the patterns of opiate use from smoking opium to injectingciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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conducted in 2011, 6.2% of people aged 15–64 years (nearly
3.5 million people) reported using an illicit drug in the last
12 months, 5.2% reported using an illicit opioid, and 0.5% reported
using heroin.16 Varying sources place the number of PWID in Iran
at between 200 000 and 300 000, with nearly 100 000 of these
residing in Tehran.17,18
Since 2002, to curb the blood-borne epidemic among PWID, Iran
has adopted and rapidly rolled out harm reduction policies
promoting opioid substitution treatment (OST), needle and syringe
programs (NSP), and outreach and prison-based programs.19
Nevertheless, the HCV epidemic continues to pose an emerging
public health threat in Iran.20While there have been several sporadic
HCVserological surveys among PWID in the last decade, a systematic
approach to assess HCV distribution and trends in various sub-
populations in Iran is lacking. The objective of this study was to
systematically compile and synthesize the epidemiological evidence
on the prevalence of HCV infection and its co-infection with HIV and
HBV among drug users outside of prison in Iran. This information
could assist policy-makers in public health decision-making with
regard to interventions targeted at reducing the burden of HCV.
2. Methods
2.1. Overview
A systematic review was conducted to identify studies
reporting the prevalence and incidence of HCV infection and its
co-infections with HIV and HBV among drug-using populations in
Iran. The following four steps were undertaken: (1) searches to
identify scientiﬁc documents, (2) screening of documents to
identify eligible studies, (3) data extraction from the studies
included, and (4) data organization, pooling, and analysis. Details
of these steps are provided below.
2.2. Conducting searches and identifying scientiﬁc documents
This step included three components. First, the strategy
employed in another systematic review conducted recently by
this study team21 was used to search several international
(PubMed, Web of Science, CINAHL, PsycINFO), regional (IMEMR),
and Iranian (Iranmedex, Iranpsych) databases. Given the scarcity of
data related to Iran, a broad search was conducted using keyword
combinations for geographic location (i.e., country and province
names) and diseases (i.e., HCV, HIV, and HBV). The search
parameters were not limited to a speciﬁc sub-population (e.g.,
drug users), language, or time interval. Instead, the documents
retrieved were screened manually and all that met the eligibility
criteria, as described below, were included. For Iranian databases,
both Persian and English keywords were used. Since the use of
combinations of keywords was not possible for these databases, a
single broad search term was used to yield a more sensitive search.
All citations identiﬁed through international databases were
imported to an Endnote library and duplicate citations were
removed. For Iranian databases, retrieved citations were reviewed
in Microsoft Word and eligible titles were entered manually into
the Endnote database, as the automatic export of citations to
Endnote was not available for these databases. Second, the
reference sections of relevant review articles (i.e., review studies
with similar eligibility criteria and scope as the present review)
and national program reports were hand-searched to identify
studies with original data. Third, researchers in the ﬁeld of drug use
and infectious diseases in several academic and public health
organizations in Iran and internationally were contacted and asked
for additional reports of original data that may have been missed in
this search.2.3. Screening of scientiﬁc documents
2.3.1. Eligibility criteria
The objective of screening was to identify scientiﬁc documents
with epidemiological evidence on the prevalence and/or incidence
of HCV infection and its co-infection with HBV or HIV among drug-
using populations who were not in a correctional facility (including
prison) or inpatient healthcare facility during or immediately
before the time of the survey. The following ﬁve eligibility criteria
were used in the selection of relevant studies: document type,
study design, disease area, geographic setting, and population.
With respect to the document type, all scientiﬁc documents
reporting original data (i.e., gathered directly by conducting
surveys and laboratory tests on specimens), in the form of a peer-
reviewed manuscript, progress report, abstract, technical report, or
substantive scientiﬁc commentary, were included. Documents not
reporting epidemiological data (e.g., legal cases, legislation) and
those not reporting original data (e.g., data simulation), as well as
documents lacking scientiﬁc and methodological details needed
for the assessment of the validity of ﬁndings (e.g., media reports)
were excluded. Documents that were self-described as ‘systematic
reviews’ or ‘meta-analyses’ (scientiﬁc documents such as peer-
reviewed manuscripts or abstracts summarizing results from a
group of epidemiological studies) were retained for hand searching
of the references.
All study designs reporting data on the prevalence and
incidence of disease, including cross-sectional studies, cohort
studies, and even experimental studies (e.g., randomized con-
trolled trials) in which a biological survey was conducted to test for
HCV prior to the introduction of the intervention (baseline) were
included. Case reports, case series, and qualitative studies were
excluded. Studies with a sample size less than 20 were considered
to be underpowered and also prone to a wider range of biases due
to a narrow implementation scale and thus were also excluded.
For the disease area, studies with biological evidence on mono-
infection with HCV and/or its co-infection with HBV or HIV were
included. Self-reported data on the above diseases were excluded.
The geographic scope was limited to studies conducted within
Iran; studies conducted among Iranian populations residing
outside of Iran were not included.
For the study population, studies conducted in human subjects
who self-identiﬁed as current or former drug users and at the time
of the study were not hospitalized or in prison (i.e., facilities under
the direct supervision of the Prison Organization, which may
contain a mix of drug- and non-drug-related offenders) were
included. Studies on populations who were in short-term
mandatory drug treatment and rehabilitation detention centers
were included. Studies in non-human subjects, blood donors,
hospitalized patients (regardless of injection drug use status),
dialysis patients, pregnant women, families or sexual partners of
HCV/HBV patients, and populations with other chronic diseases
(e.g., studies reporting HCV among people with liver cancer) were
excluded. No limits were set on study implementation or
publication age.
2.3.2. Screening process
Studies were screened in a stepwise fashion. First, one of the co-
authors (SN) carefully reviewed and excluded studies that clearly
did not meet the eligibility criteria solely based on the title (e.g.,
not related to HCV, HBV, HIV, not conducted in Iran, conducted
among speciﬁc groups such as blood donors). Subsequently, at the
abstract level, two co-authors (SN and AL) independently screened
citations to identify eligible studies. Citations included by either of
the two reviewers were put forward for full-text review. At the full-
text level, two reviewers (SN and AL) screened studies indepen-
dently and included studies that provided relevant data on the
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co-infection with HBV or HIV. Citations for which there was
disagreement were discussed by the two reviewers until consen-
sus was reached; a third co-author provided input as needed.
2.4. Data extraction
Two of the co-authors (SN and AL) independently extracted
data from the selected studies using structured sheets in
Microsoft Excel. Disagreements were discussed with a third co-
author (MM) when required. The following data were extracted:
authors (or principal investigator), publication year, publication
type, language of the publication, study implementation year,
study setting (e.g., drug treatment clinic, drop-in center (DIC),
community), study scale (clinic, city, province, national), study
target population (including eligibility criteria and history of drug
use), sample size and sampling methods, number of recruitment
sites, geographic location (urban vs. rural), key socioeconomic
indicators (age, sex, marital status, employment status, housing
status, education level), outcome measurement (specimen type,
laboratory test), outcome including prevalence of HCV mono-
infection (overall and broken down by history of incarceration,
needle sharing, tattoos), and prevalence of HCV co-infection with
HIV or HBV.
If information was missing from a study, the study authors were
contacted for further clariﬁcation. For research studies reported in
multiple formats (i.e., technical report, peer-reviewed paper, and
conference abstract), the most comprehensive and accessible
format was considered and the other documents used to
supplement missing information. The original databases of one
of the studies were obtained and used for a secondary data analysis
(Malekinejad, 2008).
2.5. Assessment of the risk of bias
An existing and validated risk of bias assessment tool was
adapted and used to rate the quality of evidence included in the
meta-analysis.22 In brief, the modiﬁed tool consisted of eight
domains, three focusing on external validity and ﬁve on internal
validity of the data. The external validity domains included the
following: (1) relevance of the target population (i.e., was the study
target population a close representation of Iranian drug users), (2)
appropriateness of the sampling method (i.e., was some form of
random sampling or other innovative method used to select the
sample), and (3) likelihood of non-response bias (i.e., was there a
high response rate or an analysis indicating that responders and
non-responders were similar). The internal validity domains
included the following: (1) directness of data collection from
subjects (i.e., were the data collected directly from the subjects or
by proxy), (2) acceptability of the case deﬁnition (i.e., was the case
deﬁnition for HCV acceptable), (3) reliability and validity of
laboratory tests (i.e., were the laboratory tests used for HCV
diagnosis shown to be valid and reliable), (4) consistency of data
collection methods for all subjects (i.e., were the methods
employed for collecting data among different participants consis-
tent), and (5) appropriateness of the numerator and denominator
of the parameters (i.e., were the numerator and denominator used
for the calculation of HCV prevalence appropriate). Two co-authors
(AL and SN) independently rated studies on the eight domains;
disagreements were resolved by discussion, and when needed, the
third co-author (MM) made tie-breaking decisions.
Each domain was ranked as a high or low risk of bias domain. On
aggregate, a three-tier ranking system (high, moderate, low) was
used to rank the selected studies as follows: (1) high risk of bias:
studies with two or more high risk of bias domains; (2) moderate
risk of bias: studies with only one high risk of bias domain; (3) lowrisk of bias: studies without any high risk of bias domain. For
studies presenting duplicate data, the version providing the most
comprehensive and complete information allowing the appraisal
of data points was reviewed.
2.6. Data synthesis
Tables were created in Microsoft Excel to organize and
synthesize the data. Studies were categorized based on self-
reported drug injection behaviors of the participants. Studies in
which participants reported no history of drug injection were
deﬁned as ‘never injector’ (NI). Those in which subjects reported
injecting drugs at least once in the year prior to the survey, or the
subjects self-identiﬁed as current injectors and had injection
marks, were deﬁned as ‘recent injector’ (RI). Finally, those studies
in which participants reported some history of drug injection but
the timing of drug injection was not deﬁned were considered as
‘ever injector’ (EI). If a study had both RI and EI populations, it was
categorized as an EI study. Studies reporting on a combination of NI
and EI or NI and RI were listed twice and prevalence data for each
population were presented separately. Summary point estimates
and 95% conﬁdence intervals (CI) were calculated for HCV, HCV/
HIV, and HCV/HBV weighted by inverse of variance, using a
random-effects meta-analysis model in Stata version 13 with the
metan command. Data for the above sub-populations were
presented in the form of forest plots wherever such data were
available. The meta-analysis was also repeated on a sub-set of
studies that were ranked as low or moderate risk of bias studies. In
circumstances where the distribution of the pooled prevalence was
not normal or the pooled prevalence was close to 0 or 100 and the
sample size was small, using a traditional meta-analysis command
(metan command in Stata) would have resulted in CIs smaller than
zero or larger than 100. To address this issue, the prevalence and CI
were ﬁrst transformed into the logit scale in order to generate a
distribution closer to normal, and meta-analyses were then
performed on the transformed values. Overall pooled prevalence
and CIs were derived by back-transforming the estimates and CIs
using the ‘invlogit’ function. In a few cases, the CI of pooled
prevalence data remained smaller than zero or larger than
100 even after using the logit transformation. For these data
points, CIs for the original data were calculated using the exact
binomial and score test with the metaprop command in Stata.
3. Results
Of the total 3401 scientiﬁc documents retrieved from the
electronic searches (after de-duplication), hand-searching of
review studies and reports, and contacting experts, 32 relevant
scientiﬁc documents were identiﬁed and included. A total of
24 experts were contacted, 11 of whom responded, yielding a total
of 18 new documents. Four new documents sent by the research
experts met the eligibility criteria and were included in the
32 documents for ﬁnal assessment and potential data extraction.
The 14 other documents were eliminated because the subjects
were prison inmates (Figure 1).
From the ﬁnal list of 32 documents, 23 (72%) were in English23–45
and nine (28%) were in Persian.46–54 Thirty documents were peer-
reviewed articles23–52,54 and two were technical reports.53 Of the
32 documents included, eight reported the same data as other
studies (six duplicates and one triplicate); hence there were
24 original studies. The eight duplicate studies were not included
in the ﬁnal meta-analysis but were used to complete key
information when data points were missing from the original
document reporting on the same study.
Table 1 presents the characteristics of the research studies
included in the review. Of the 24 original studies, nine (37.5%)
Figure 1. Search results: number of studies identiﬁed at each step of the search, screening, and data extraction process.
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EI,29–31,33,35–37,41,46,54 and one (4.2%) was a study on NI.43 Another
four (16.7%) studies reported on both EI and NI.27,42,47,50 These four
studies are presented twice in Table 1, once among the EI population
and a second time among the NI population. The studies included
were carried out within an 11-year time span (2001–2012), with
more than half being implemented between 2006 and 2012. With
respect to the geographic location, eight (33.3%) studies were
conducted only in Tehran (the capital city),24–26,31–33,43,44 12 (50.0%)
in a city other than Tehran,27,29,30,36,37,40,42,45–47,50,54 and four
(16.7%) in multiple cities.23,35,41,53 All studies implemented cross-
sectional designs and two applied respondent-driven sampling
(RDS) for participant recruitment.32,45With respect to study setting,three (12.5%) recruited subjects from DIC,23,35,37 seven (29.2%)
from drug treatment clinics,25,29,31,33,40,47,50 two (8.3%) from the
community,36,46 one (4.2%) from homes,42 four (16.7%) from health
facilities including voluntary HIV counseling and testing (VCT)
sites,27,30,43,54 one from a detention center (4.2%),26 and ﬁve (20.8%)
from a mix of settings.24,32,44,45,53 One study did not report the
recruitment setting.41 All studies used whole blood, except for one
that used saliva44 and one that used dried blood samples.53
Table 2 presents a summary of the demographic and
socioeconomic characteristics of the 13 821 study subjects. The
overall weighted mean age of subjects was 32.4 years (95% CI 31–
33 years). Among all subjects, 87.4% (95% CI 82–92%) were male,
53.9% (95% CI 47–60%) were unmarried, 54.6% (95% CI 42–66%)
Table 1
Characteristics of the populations and studies included in the systematic review
Author/principal
investigator, publication
year, and language
Characteristics of the population Characteristics of the study
Age, years, mean
(SE) min–max
% Male Sample, SESa Study year and
location
Scale and
number of sites
Study settingb Biological testc Sampling method Sample sized
Recent IDU
Alipour 2013
(English)
36.4e 84% Unmarried: 44.8%
Under-educated: 74.2%
Tehran, Mashad,
Shiraz (2010)
City (multiple) DIC HCV: ELISA and
WB
HIV: ELISA and
WB
HBV: ELISA
Convenience 268
Amin-Esmaeili 2012
(English)
Rahimi-Movaghar 2010
(English)
33.9 (9.4)
16–65
95.80% Unmarried: 70.8%
Under-educated:53.4%
Homeless: 38.8%
Unemployed: 64.1%
Imprisoned: 70.9%
Tehran (2006) City (multiple) Mixed (drug
treatment clinic,
DIC, community)
HCV: ELISA
HIV: ELISA and
WB
HBV: EIA and
IEMA Well
Purposive and
snowballing
(community)
Convenience (drug
treatment centers)
904
Amini 2005
(English)
NR NR NR Tehran (2002) City (single) Drug treatment
clinic
HCV: EIA
HIV: EIA
HBV: EIA
Convenience 34
Eskandarieh 2013
(English)
28.78
13–62
96.50% Unmarried: 76.2%
Under-educated: 70.4%
Homeless: 37.0%
Unemployed: 14.8%
Imprisoned: 72.7%
Tehran (2008) City (single) Detention center
(Shafagh)
HCV: NR
HIV: ELISA and
WB
Convenience 402
Malekinejad 2008f
(English)
Rahnama 2014
(English)
36.5 (9.2)
20–70
99.40% Unmarried: 46%
Under-educated: 45.7%
Homeless: 34.9%
Unemployed: 45.8%
Imprisoned: 83.2%
Tehran (2007) City (multiple) Mixed (hospital,
DIC)
HCV: ELISA
HIV: EIA
HBV: NR
Respondent-driven 564
Noroozi 2011f
(Persian)
35.96 (8.03)
20–54
95.3% Unmarried: 29.7%
Under-educated: 62.5%
Homeless: 10.4%
Unemployed: 32.8%
Karaj, Isfahan,
Gorgan (2011)
City (multiple) Mixed (drug
treatment clinic,
DIC)
HCV: ELISA Convenience 192
Ramezani 2014f
(English)
Median 33.3
17–58
100% Unmarried: 67%
Under-educated: 70%
Unemployed: 17%
Imprisoned: 73%
Arak (2012) City (single) Drug treatment
clinic
HCV: ELISA
HIV: ELISA and
WB
HBV: ELISA
Convenience 100
Zamani 2007
(English)
38.3 (11.9)
15–64
97% Unmarried: 41.1%
Under-educated: 75.2%
Homeless: 32.2%
Unemployed: 65.8%
Tehran (2004) City (multiple) Mixed (DIC and
community)
PA assays Convenience 202
Zamani 2010
(English)
29.0 (6.6) 97.40% Unmarried: 69.2%
Under-educated: 54.7%
Unemployed: 42.7%
Foulad-shahr
(2008)
City (multiple) Mixed (NEP, MMT,
community, DIC)
HCV: ELISA
HIV: EIA
HBV: NR
Respondent-driven 118
Ever IDU
Ataei 2011
(Persian)
NR NR NR Golpayeganh
(2007)
City (multiple) Community HCV: ELISA Convenience 136
Azizi 2011i
(Persian)
31.82 (9.18)g NR Unmarried: 51%
Under-educated: 66.5%
Unemployed: 14.8%
Kermanshah
(2008)
City (single) Drug treatment
clinic
HCV: ELISA Convenience 263
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Honarvar 2013i
(English)
32.3 (7.33)
19–59
98.3% Unmarried: 70.8%
Under-educated: 14.2%
Unemployed: 26.6%
Shiraz
(2012)
City (multiple) VCT HCV: ELISA and
WB
HIV: ELISA and
WB
HBV: ELISA
Convenience 569
Fadaei Nobari 2012
(English)
Fadaei Nobari 2011
(Persian)
35 (9.4)
17–64
NR NR Isfahan Provinceh
(2008)
Province (multiple) Community HCV: ELISA Convenience 1747
Imani 2008
(English)
Imani 2006
(Persian)
31.3 (7.1)
18–65
98.40% NR Shahr-e-Kord
(2004)
City (multiple) Drug treatment
clinic
HCV: ELISA Convenience 133
Keramat 2011
(English)
29.7 (9.5)
13–80
71.50% Imprisoned: 52.5% Hamadan (2005) City (single) VCT HCV: ELISA and
WB
HIV: ELISA and
WB
Convenience 379
Kheirandish 2009
(English)
Hosseini 2010
(English)
33.7 (10.2)
17–70
100% Unmarried: 60.4%
Under-educated: 81.1%
Imprisoned: 75.3%
Tehran
(2006)
City (single) Drug treatment
clinic
HCV: EIA
HIV: ELISA and
WB
Convenience 454
Khodadadi-zadeh 2006i
(Persian)
29.3 (5.3) 95.50% NR Rafsanjan (2003) City (single) Drug treatment
clinic
HCV: ELISA
HIV: ELISA and
WB
HBV: ELISA
Convenience 180
Mirahmadizadeh 2009
(English)
33.1 (8.97)
15–63
96.10% Unmarried: 64.9% Multiple cities
(2005)
National (multiple) DIC NR Systematic,
random
1531
Mir-Nasseri 2008
(English)
Mir-Nasseri 2011
(English)
Mir-Nasseri 2005
(Persian)
33 (8.66)
19–54
98% NR Tehran
(2001)
City (multiple) Drug treatment
clinic
HCV: ELISA
HIV: NR
HBV: EIA
Convenience 132
Nokhodian 2012
(English)
Meshkati 2011
(Persian)
31.77 (8.51)
19–62
94.70% Unmarried: 47.6%
Under-educated: 19.9%f
Unemployed: 44.1%
Isfahan (2008) Province (multiple) DIC HCV: ELISA Convenience 539
Rostami Jalilian 2006
(Persian)
27.7 (7.6)
16–54
NR NR Isfahan (2002) City (multiple) VCT HCV: ELISA Convenience 148
Sarkari 2012
(English)
NR 66.40% Unmarried: 39.7% Yasuj, Gachsaran,
Dehdasht,
Kohgilooye
Province (2009)
Province (multiple) NR HCV: ELISA Convenience 158
Sayad 2008i
(English)
32.7 (12.5)e
15–64
49.60% Unmarried: 38.5%
Under-educated: 54.7%
Kermanshah
(2006)
City (multiple) Home-based ELISA and WB Systematic and
cluster
1721
Never IDU
Azizi 2011i
(Persian)
31.82 (9.18)g NR Unmarried: 51%
Under-educated: 66.5%
Unemployed: 14.8%
Kermanshah
(2008)
City (single) Drug treatment
clinic
HCV: ELISA Convenience 263
Honarvar 2013i
(English)
28.49 (7.72)
13–56
75.90% Unmarried: 63.7%
Under-educated: 11.3%
Unemployed: 25.6%
Shiraz
(2012)
City (multiple) VCT HCV: ELISA and
WB
HIV: ELISA and
WB
HBV: ELISA
Convenience 569
Khodadadi-zadeh 2006i
(Persian)
29.3 (5.3) 95.50% NR Rafsanjan (2003) City (single) Drug treatment
clinic
HCV: ELISA
HIV: ELISA and
WB
HBV: ELISA
Convenience 180
Sayad 2008i
(English)
32.7 (12.5)e
15–64
49.60% Unmarried: 38.5%
Under-educated: 54.7%
Kermanshah
(2006)
City (multiple) Home-based
ELISA and WB
Systematic and
cluster
1721
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M. Malekinejad et al. / International Journal of Infectious Diseases 40 (2015) 116–130122were under-educated (deﬁned as having lower than a high school
diploma), 30.3% (95% CI 17–42%) were homeless (data available
only for RI), 34.1% (95% CI 23–45%) were unemployed at the time or
within the year prior to the study, and 71.3% (95% CI 63–79%)
reported ever being imprisoned.
As shown in Figure 2, the overall pooled HCV prevalence among
all injection drug users (IDU) (RI and EI combined) was 45% (95% CI
37–54%).23–27,29–33,35–37,40–42,44–47,50,53,54 The HCV prevalence
among RI was 53% (95% CI 37–70%)23–26,32,40,44,45,53 and in EI it
was 40% (95% CI 30–50%).27,29–31,33,35–37,41,42,46,47,50,54 The preva-
lence of HCV among NI was 8% (95% CI 4–13%)27,42,46,47,50
(Figure 3).
Among the 24 original studies, 15 (63%) had a high risk of bias,
seven (29%) had a moderate risk of bias, and two (8%) had a low risk
of bias (Table 3). After excluding the 15 studies with a high risk of
bias, the overall pooled HCV prevalence among all IDU was 53%
(95% CI 38–68%).31,33,35,42,44,45,47,54,55 The HCV prevalence among
RI was 65% (95% CI 43–88%)44,45,55 and among EI was 46% (95% CI
27–65%).31,33,35,42,47,54 The HCV prevalence among NI was 6% (95%
CI 3–9%).42,47
The pooled prevalence of HCV co-infection with HIV and HBV in
all IDU was also examined. In total, 2615 individuals were tested
for both HCV and HIV, while 1996 individuals were tested for HCV
and HBV. The prevalence of HCV/HIV and HCV/HBV co-infection
among IDU was 11% (95% CI 5–16%)24,27,31–33,40,44,45 and 11% (95%
CI 2–20%),24,27,32,33,40,45 respectively (Figure 4).
With respect to the distribution of HCV infection among IDU by
geographic location, pooled estimates of HCV prevalence in
Tehran, cities other than Tehran, and a mix of Tehran and other
cities were 55% (95% CI 35–74%),24–26,31,33,44 42% (95% CI 30–
54%),27,29,30,32,36,37,40–42,45–47,50,53,54 and 41% (95% CI 37–46%),23,35
respectively. Further, when the distribution of infection by
recruitment setting was assessed, the pooled HCV prevalences
were as follows: 43% (95% CI 17–69%) among those recruited from
drug treatment clinics,25,29,31,33,40,47,50 43% (95% CI 39–48%) among
those recruited from DIC,23,35,37 48% (95% CI 32–63%) among those
recruited from healthcare facilities,27,30,54 40% (95% CI 18–62%)
among those recruited from the community,26,36,46 50% (95% CI
22–78%) among those recruited from the home,42 and 52% (95% CI
27–77%) among those recruited from a mix of settings
(Figure 5).24,32,44,45,53
As presented in Table 4, the pooled HCV prevalence was higher
among IDU with a history of incarceration (58%, 95% CI 39–77%) as
compared to those without such a history (44%, 95% CI 20–68%).
HCV prevalence was also higher among those IDU with a history of
tattoos (72%, 95% CI 55–88%) as compared to those without this
history (55%, 95% CI 40–70%). Further, IDU who reported sharing
needles in the past had higher rates of HCV (57%, 95% CI 41–71%)
than those who reported not sharing needles (49%, 95% CI 26–71%).
The differences in these three categories were not considered
statistically signiﬁcant.
4. Discussion
PWID are the main group affected by HCV infection world-
wide.56 This study examined the prevalence of HCV among drug
users with and without a drug injection history. The results
showed a high prevalence of HCV infection among PWID in Iran,
which is consistent with world estimates of 52.0% in this
population,6 but still lower than the prevalence reported in certain
other countries (e.g., Bulgaria, Estonia).1 HCV infection can lead to
serious and deadly liver diseases such as cirrhosis and hepatocel-
lular carcinoma. The burden of hepatitis C attributed to injection
drug use is high and was estimated to be 502 000 (286 000–891
000) disability-adjusted life-years globally in 2010.57 Given that
HCV prevalence in Iran is consistent with world estimates, HCV
Table 2
Summary of the demographic and socioeconomic characteristics of participants in the studies included, by pattern of drug injection
Sample size Age, years Male Unmarried Under-educated Homeless Unemployed Ever imprisoned
N Mean (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Recent IDU 2784 34.7 (32–37) 95.6 (93–97) 55.5 (43–67) 63.1 (54–71) 30.3 (17–42) 40.4 (23–57) 75.1 (68–82)
Ever IDU 8090 31.8 (30–32) 85.5 (76–94) 53.3 (42–64) 47.2 (22–72) - 38.5 (12–44) 63.9 (41–86)
Any IDU (combined above) 10874 32.6 (31–33) 89.9 (85–94) 54.5 (46–62) 57.1 (44–69) - 36.8 (24–49) 71.3 (63–79)
Never IDU 2947 31.9 (29–34) 78.1 (54–100) 51.1 (33–68) 44.1 (10–77) - 20.2 (9–30) -
Overall 13821 32.4 (31–33) 87.4 (82–92) 53.9 (47–60) 54.6 (42–66) 30.3 (17–42) 34.1 (23–45) 71.3 (63–79)
CI, conﬁdence interval; IDU, injection drug user.
M. Malekinejad et al. / International Journal of Infectious Diseases 40 (2015) 116–130 123likely contributes to a high burden of disease in Iran. Therefore,
special emphasis must be placed on the control of HCV infection
among PWID in Iran.
In 2002, Iran implemented harm reduction interventions
including NSP and OST, primarily in response to the HIV epidemics
among PWID. These programs have been scaled up at the national
level since 2007.19 Although there is ample evidence on theFigure 2. HCV prevalence in injecting drug users (IDU): summary estimate of HCV infectio
of injection.effectiveness of NSP and OST in the reduction of self-reported
injecting risk behaviors,58–60 evidence regarding the effectiveness
of these programs in reducing HCV incidence is inconclusive.58,59
HCV infection is transmitted more efﬁciently than HIV.61–66
Modeling studies have shown that an individual who shares
needles and syringes is at greatest risk of contracting HCV during
the ﬁrst year.67,68 In addition, the risk of becoming infectedn prevalence and 95% conﬁdence interval among people who inject drugs, by timing
Figure 3. HCV prevalence in drug users who do not inject (non-IDU): summary estimate of HCV infection prevalence and 95% conﬁdence interval among drug users who have
never injected.
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Cohort study, the incidence of HCV infection among PWID who
received both OST and high coverage NSP (i.e., sufﬁcient numbers
of syringes) was approximately one third lower than that of those
who received either OST or NSP alone.60 These studies suggest that
a combination of harm reduction interventions need to reach PWID
early on to be effective in reducing the risk of HCV transmission.
This is especially applicable to Iran, since the overall coverage of
the NSP and OST programs has remained insufﬁcient among
PWID8,71 and many harm reduction facilities provide only one or
the other.
In this study, the weighted pooled prevalence (11.3%) of HCV
and HIV co-infection among PWID in Iran was also calculated. A
recent systematic review of 22 European countries reported a
median co-infection rate of 3.9%.70 HIV co-infection accelerates
disease progression in chronic hepatitis C and reduces the response
rate to interferon-based therapy.72 Further, there is a higher risk of
hepatotoxicity among HIV-infected patients treated with antire-
troviral therapy (ART) who are co-infected with HCV.73–75 Direct-
acting antivirals (DAA) are equally effective in HCV patients with
and without HIV co-infection and may be a better treatment choice
for this population.76 However the cost of treatment limits their
availably in Iran. It was not possible to provide a pooled prevalence
of HCV and HIV co-infection among drug users who had never
injected drugs, because only one study reported these data on NI.
In the study sample, non-IDU had a higher prevalence of
hepatitis C (8.2%) than the general population (<1%).20 Some
studies on HCV infection among individuals with no reported
history of blood transfusion and injection drug use have proposed
sexual intercourse as the possible mode of HCV transmission.77,78
The authors suspect that in this review, a high degree of mixing orbridging between IDU and non-IDU may have resulted in the high
HCV prevalence. The higher than expected HCV infection among
non-IDU may also be due to a multitude of other risk factors, such
as unsafe tattoo procedures, body piercings, cocaine snorting,
crack-cocaine use, herpes simplex virus (HSV)-2 infection, gonor-
rhea, HIV infection, and high-risk sexual activity.78–83 HCV
infection among non-IDU is likely also inﬂuenced by under-
reporting of injection practices, as a result of the stigma attached to
injection drug use, which leads to the misclassiﬁcation of drug
users.84,85 Further studies are needed to determine the risk factors
for HCV infection among non-IDU. Such studies should also focus
on the extent to which the stigma associated with injection drug
use may deter PWID from reporting injection behaviors.
It should be noted that studies that assessed HCV prevalence in
incarcerated drug users were excluded from this review. HCV
prevalence in this sub-population might be higher than in those
out of prison. Nonetheless, more than 70% of drug users included in
this review had a history of imprisonment in their lifetime.
Although HCV prevalence was higher in those with a history of
incarceration, the difference was non-signiﬁcant. The Prison
Organization in Iran launched small-scale programs to provide
sterile needles and syringes to prisoners who inject drugs in a
limited number of prisons, but these programs were not scaled
up.19 Another systematic review by our team is underway to
determine the prevalence of HCV among incarcerated populations
in Iran.
The sharing of injection equipment is the primary cause of HCV
transmission;2 however, no correlation was found between a self-
reported history of needle sharing and HCV prevalence. Because
many of the studies included in this review did not report
information on the sharing of injection equipment other than
Table 3
Assessment of risk bias of studies included in the systematic review
Author and year External validity Internal validity
Relevance of
target
population
Appropriateness
of sampling
method
Likelihood of
non-response
bias
Directness of
data collection
from subjects
Acceptability of
case deﬁnition
Reliability
and validity of
laboratory tests
Consistency
of data
collection
methods
for all
subjects
Appropriateness
of numerator
and denominator
of parameters
Overall
risk
of biasa
Alipour 2013 Low High High Low Low Low Low Low High
Amin-Esmaeili 2012
Rahimi-Movaghar 2010
Low High High Low Low Low Low Low High
Amini 2005 High High High Low Low Low Low Low High
Eskandarieh 2013 High High High Low Low Low Low Low High
Malekinejad 2008
Rahnama 2014
Low Low Low Low Low Low Low Low Low
Noroozi 2011 Low High High Low High High Low Low High
Ramezani 2014 High High High Low Low Low Low Low High
Zamani 2007 Low High Low Low Low Low Low Low Moderate
Zamani 2010 Low Low Low Low Low Low Low Low Low
Ataei 2011 Low High High Low Low Low Low Low High
Azizi 2011 High Low Low Low Low Low Low Low Moderate
Honarvar 2013 High High High Low Low Low Low Low High
Fadaei Nobari 2012
Fadaei Nobari 2011
Low High High Low Low Low Low Low High
Imani 2008
Imani 2006
High High High Low Low Low Low Low High
Keramat 2011 High High High Low Low Low Low Low High
Kheirandish 2009
Hosseini 2010
Low High Low Low Low Low Low Low Moderate
Khodadadi-zadeh 2006 High High High Low Low Low Low Low High
Mirahmadizadeh 2009 Low Low High Low Low Low Low Low Moderate
Mir-Nasseri 2008
Mir Nasseri 2011
Mir-Nasseri 2005
Low High Low Low Low Low Low Low Moderate
Nokhodian 2012
Meshkati 2011
Low High High Low Low Low Low Low High
Rostami Jalilian 2006 Low High Low Low Low Low Low Low Moderate
Sarkari 2012 Low High High Low Low Low Low Low High
Sayad 2008 Low Low High Low Low Low Low Low Moderate
Talaie 2007 High High Low Low Low Low Low Low High
a Low: no high-risk domains; moderate: one high-risk domain; high: two or more high-risk domains.
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noteworthy that a recent meta-analysis of the factors correlated
with HCV transmission in China showed no signiﬁcant difference
between those who shared injection equipment and those who did
not.86
Studies among Iranian PWID have shown that testing for
blood-borne infectious diseases in this population is low.53,71
Since there are multiple studies supporting the successful
treatment of HCV among PWID,87,88 easy access to testing
services could be an initial step towards meeting the need for
HCV infection treatment. In Iran, there is no publicly funded
program for the treatment of HCV infection. Besides, insurance
coverage for antiviral medications and the tests required are very
limited. These issues negatively affect access to antiviral
treatment for affected populations, particularly people who use
drugs in Iran. Treatments may also have a positive impact on
preventing HCV transmission. Modeling studies suggest that new-
generation antiviral therapies could be a cost-effective and
efﬁcacious method of preventing HCV transmission among
affected individuals while they are in treatment and once a
sustained virological response has been achieved.89,90
Although the studies were heterogeneous with respect to the
risk of bias, the overall quality of evidence was found to be low,
with only two out of the 24 studies qualifying as low risk of bias
studies. Nevertheless, the estimated pooled prevalence of HCV
among all sub-populations of drug users (RI+EI, RI only, EI only,and NI) remained relatively stable (i.e., 95% CI overlapped
signiﬁcantly) after the 15 studies that were rated as having a
high risk of bias were excluded from the meta-analysis.
Although the prevalence remained relatively stable, this change
resulted in a wider 95% CI for estimates as a result of a decrease
in the number of subjects included in the model. For all drug-
injecting sub-populations (RI+EI, RI, and EI), the distribution of
the HCV prevalence shifted to the right (i.e., the prevalence
increased), while among NI, the distribution shifted to the left
(the prevalence decreased). In addition to heterogeneity with
regard to the risk of bias, the studies included in this review were
also heterogeneous with respect to study setting and the
characteristics of the drug-using sub-populations. The wide
conﬁdence intervals around the pooled estimates generated by
the random-effects model reﬂect the uncertainty around these
estimates.
Given the present ﬁndings of high HCV prevalence in drug
users, providing an appropriate response to HCV infection within
this population in Iran is warranted. Such a response would likely
require urgent implementation of a multi-pronged approach
consisting of a combination of preventive measures, testing
services, and antiviral treatment programs among drugs users,
particularly PWID. Further studies are needed to provide
evidence based on target coverage and a combination of harm
reduction interventions to reduce HCV transmission among
Iranian PWID.
Figure 4. HCV co-infection prevalence: summary estimate of HCV/HIV (top) and HCV/HBV (bottom) co-infection prevalence and 95% conﬁdence interval, by drug use pattern.
M. Malekinejad et al. / International Journal of Infectious Diseases 40 (2015) 116–130126
Figure 5. HCV prevalence in different cities/settings: summary estimate of HCV infection prevalence and 95% conﬁdence interval among injection drug users, stratiﬁed by city
(top) and study setting (bottom).
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